Haemonetics (HAE) investor relations material

Company overview and recent performance

• Approaching $1.4 billion in revenue with diversified MedTech operations and global leadership in plasma apheresis, supported by robust free cash flow and high return on invested capital.

• Achieved all targets set in the four-year long-range plan, including high single-digit revenue growth, 800+ basis points of operating margin expansion, $600–$700 million cumulative free cash flow, and $3 EPS growth.

Plasma business and innovation

• Plasma segment is experiencing record performance, driven by sustained share gains, innovation, and pricing, with strong end-market demand for plasma-derived therapies.

• Recently launched Persona PLUS, offering a mid-single digit yield increase over Persona, backed by a pivotal trial and immediate commercialization plans.

• Customer relationships are deepening, with global standardization around the integrated NexSys, Persona, and NexLynk ecosystem, enhancing productivity and donor safety.

• Share gains with existing customers are the largest revenue driver, with 20% growth this year and expectations to maintain global market leadership.

• Competitive differentiation is reinforced by proprietary software and integrated platforms, with ongoing innovation cycles planned beyond Persona PLUS.

Hospital and interventional technologies

• Interventional Technologies franchise prioritizes returning to above-market growth, with confidence in long-term trajectory despite recent competitive and macro challenges.

• Anticipates momentum from ASC site-of-care shifts, MVP label expansion in the US and Japan, stronger clinical evidence, and the Vivasure acquisition for PerQseal Elite launch.

• Largest dedicated vascular closure sales force established, with improved coverage and incentives, now showing early operational improvements.

• OpSens' SavvyWire is positioned for growth after inventory headwinds, while Attune faces market timing challenges; vascular closure remains the core IVT growth pillar.

• PerQseal Elite addresses a $300 million global TAM in large bore closure, leveraging existing sales force and offering a differentiated, suture-less, bioabsorbable solution.

• Launch strategy for PerQseal Elite is phased, focusing on training, manufacturing readiness, and targeted, time-bound investment.